Global Left Ventricular Dysfunction Drug Pipeline Trends 2019: Discovery, Pre-clinical, Clinical, In Approval Therapeutics, Companies and Markets
High levels of pipeline activity are being observed in Left Ventricular Dysfunction treatment during 2019. Clinical development activities are being undertaken by more than 5 companies including Armaron Bio Pty Ltd., Bayer AG, Innopharmax Inc., Mesoblast Ltd, Quantum Genomics Corp. and others.
A Significant contribution to the Left Ventricular Dysfunction pipeline is being observed from emerging companies opting for new approaches to clinical development strategy. The early stage and late-stage Left Ventricular Dysfunction pipeline included 6 compounds, driven by increasing number of targeted therapies. Progress is being made in accelerating compounds into advanced stages. However, fluctuating trends are being observed in average duration across three phases.
Increased understanding of underlying causes of Left Ventricular Dysfunction condition and increased access to investments is encouraging growth of Left Ventricular Dysfunction drug pipeline. However, despite high levels of pipeline activity, increasing clinical trial costs and decreasing drug approval rates is requiring companies to focus more on understanding clinical development pipeline compounds.
The research study is structured to provide clear and actionable insights into Left Ventricular Dysfunction drug pipeline for companies to optimize spending levels by understanding competition, their pipeline products and prospect of further advances over the next few years.
The report addresses the discovery, research and pre-clinical stage active Left Ventricular Dysfunction therapeutic candidates. Further, drugs in clinical stage including phase 1, phase 2, phase 3 and pre-registration phases are also analyzed.
The current report examines the current Left Ventricular Dysfunction pipeline along with current development status, regulatory progress, mechanism of action, route of administration, collaborating companies, sponsors, molecule type, and research/discovery details.
In addition to drug overview, recent developments, the report also provides mechanism of action, Pre-clinical trial details and Clinical trial details for each of the drug candidates of Left Ventricular Dysfunction. Further, orphan drug status, fast track designation, grants awarded and other special status for Left Ventricular Dysfunction pipeline compounds are also included.
This study was produced independently by VPAResearch from our proprietary databases, primarily to assist users to develop in-depth understanding of 2019 Left Ventricular Dysfunction pipeline and formulate effective research and development strategies.
RESEARCH METHODOLOGY
Our integrated data reports are built through robust research methodology to ensure our users can build on the insights and data accuracy for their expansion plans. Both primary and secondary research methods are used with stringent quality checks at each stage to evaluate trends, analysis and forecasts.
Scope of the Research
Left Ventricular Dysfunction Pipeline candidates-
A Significant contribution to the Left Ventricular Dysfunction pipeline is being observed from emerging companies opting for new approaches to clinical development strategy. The early stage and late-stage Left Ventricular Dysfunction pipeline included 6 compounds, driven by increasing number of targeted therapies. Progress is being made in accelerating compounds into advanced stages. However, fluctuating trends are being observed in average duration across three phases.
Increased understanding of underlying causes of Left Ventricular Dysfunction condition and increased access to investments is encouraging growth of Left Ventricular Dysfunction drug pipeline. However, despite high levels of pipeline activity, increasing clinical trial costs and decreasing drug approval rates is requiring companies to focus more on understanding clinical development pipeline compounds.
The research study is structured to provide clear and actionable insights into Left Ventricular Dysfunction drug pipeline for companies to optimize spending levels by understanding competition, their pipeline products and prospect of further advances over the next few years.
The report addresses the discovery, research and pre-clinical stage active Left Ventricular Dysfunction therapeutic candidates. Further, drugs in clinical stage including phase 1, phase 2, phase 3 and pre-registration phases are also analyzed.
The current report examines the current Left Ventricular Dysfunction pipeline along with current development status, regulatory progress, mechanism of action, route of administration, collaborating companies, sponsors, molecule type, and research/discovery details.
In addition to drug overview, recent developments, the report also provides mechanism of action, Pre-clinical trial details and Clinical trial details for each of the drug candidates of Left Ventricular Dysfunction. Further, orphan drug status, fast track designation, grants awarded and other special status for Left Ventricular Dysfunction pipeline compounds are also included.
This study was produced independently by VPAResearch from our proprietary databases, primarily to assist users to develop in-depth understanding of 2019 Left Ventricular Dysfunction pipeline and formulate effective research and development strategies.
RESEARCH METHODOLOGY
Our integrated data reports are built through robust research methodology to ensure our users can build on the insights and data accuracy for their expansion plans. Both primary and secondary research methods are used with stringent quality checks at each stage to evaluate trends, analysis and forecasts.
Scope of the Research
Left Ventricular Dysfunction Pipeline candidates-
- Pre-clinical Phase: Discovery, research, pre-clinical
- Early Phase: Phase 1 and Phase 2 Left Ventricular Dysfunction drugs
- Late phase: Phase 3 and in-approval Left Ventricular Dysfunction drugs
- Company overview
- Snapshot
- Left Ventricular Dysfunction therapeutic treatment activities
- Snapshot
- Drug Name
- Alternative Names
- Company
- Originator
- Phase
- Molecule Type
- Orphan Drug Status
- Drug Overview
- Mechanism of Action
- Current Status
- Trial Details
- Pre-clinical trials for each drug candidate
- Clinical trials for each drug candidate
1 TABLE OF CONTENTS
1.1 List of Tables
1.2 List of Figures
2 EXECUTIVE SUMMARY
2.1 Left Ventricular Dysfunction- Disease Overview
2.2 Left Ventricular Dysfunction- Pipeline Snapshot
2.3 Left Ventricular Dysfunction- Pipeline Drugs by Phase
2.4 Left Ventricular Dysfunction- Pipeline Drugs by Company
2.5 Left Ventricular Dysfunction- Pipeline Drugs by Mechanism of Action
3 COMPANY WISE PIPELINE ANALYSIS
3.1 Armaron Bio Pty Ltd. Left Ventricular Dysfunction Drug Pipeline, H2- 2019
3.2 Bayer AG Left Ventricular Dysfunction Drug Pipeline, H2- 2019
3.3 Innopharmax Inc. Left Ventricular Dysfunction Drug Pipeline, H2- 2019
3.4 Mesoblast Ltd Left Ventricular Dysfunction Drug Pipeline, H2- 2019
3.5 Quantum Genomics Corp. Left Ventricular Dysfunction Drug Pipeline, H2- 2019
3.6 Takeda Pharmaceutical Co Ltd Left Ventricular Dysfunction Drug Pipeline, H2- 2019
4 PHASE 1 PIPELINE DRUG DETAILS
4.1 Left Ventricular Dysfunction- Phase 1 Drug Details
4.2 Left Ventricular Dysfunction- Phase 1 Drug Overview
4.3 Left Ventricular Dysfunction- Phase 1 Mechanism of Action
4.4 Current Status
4.5 Trial Details
5 PHASE 2 PIPELINE DRUG DETAILS
5.1 Left Ventricular Dysfunction- Phase 2 Drug Details
5.2 Left Ventricular Dysfunction- Phase 2 Drug Overview
5.3 Left Ventricular Dysfunction- Phase 2 Mechanism of Action
5.4 Current Status
5.5 Trial Details
6 PHASE 3 PIPELINE DRUG DETAILS
6.1 Left Ventricular Dysfunction- Phase 3 Drug Details
6.2 Left Ventricular Dysfunction- Phase 3 Drug Overview
6.3 Left Ventricular Dysfunction- Phase 3 Drug Mechanism of Action
6.4 Current Status
6.5 Trial Details
7 PRE-CLINICAL PHASE PIPELINE DRUG DETAILS
7.1 Left Ventricular Dysfunction- Pre-clinical Phase Drug Details
7.2 Left Ventricular Dysfunction- Pre-clinical Phase Drug Overview
7.3 Left Ventricular Dysfunction- Pre-clinical Phase Drug Mechanism of Action
7.4 Current Status
7.5 Trial Details
8 RECENT NEWS AND DEVELOPMENTS
9 APPENDIX
9.1 About VPAResearch
9.2 Sources and Research Methodology
1.1 List of Tables
1.2 List of Figures
2 EXECUTIVE SUMMARY
2.1 Left Ventricular Dysfunction- Disease Overview
2.2 Left Ventricular Dysfunction- Pipeline Snapshot
2.3 Left Ventricular Dysfunction- Pipeline Drugs by Phase
2.4 Left Ventricular Dysfunction- Pipeline Drugs by Company
2.5 Left Ventricular Dysfunction- Pipeline Drugs by Mechanism of Action
3 COMPANY WISE PIPELINE ANALYSIS
3.1 Armaron Bio Pty Ltd. Left Ventricular Dysfunction Drug Pipeline, H2- 2019
3.2 Bayer AG Left Ventricular Dysfunction Drug Pipeline, H2- 2019
3.3 Innopharmax Inc. Left Ventricular Dysfunction Drug Pipeline, H2- 2019
3.4 Mesoblast Ltd Left Ventricular Dysfunction Drug Pipeline, H2- 2019
3.5 Quantum Genomics Corp. Left Ventricular Dysfunction Drug Pipeline, H2- 2019
3.6 Takeda Pharmaceutical Co Ltd Left Ventricular Dysfunction Drug Pipeline, H2- 2019
4 PHASE 1 PIPELINE DRUG DETAILS
4.1 Left Ventricular Dysfunction- Phase 1 Drug Details
4.2 Left Ventricular Dysfunction- Phase 1 Drug Overview
4.3 Left Ventricular Dysfunction- Phase 1 Mechanism of Action
4.4 Current Status
4.5 Trial Details
5 PHASE 2 PIPELINE DRUG DETAILS
5.1 Left Ventricular Dysfunction- Phase 2 Drug Details
5.2 Left Ventricular Dysfunction- Phase 2 Drug Overview
5.3 Left Ventricular Dysfunction- Phase 2 Mechanism of Action
5.4 Current Status
5.5 Trial Details
6 PHASE 3 PIPELINE DRUG DETAILS
6.1 Left Ventricular Dysfunction- Phase 3 Drug Details
6.2 Left Ventricular Dysfunction- Phase 3 Drug Overview
6.3 Left Ventricular Dysfunction- Phase 3 Drug Mechanism of Action
6.4 Current Status
6.5 Trial Details
7 PRE-CLINICAL PHASE PIPELINE DRUG DETAILS
7.1 Left Ventricular Dysfunction- Pre-clinical Phase Drug Details
7.2 Left Ventricular Dysfunction- Pre-clinical Phase Drug Overview
7.3 Left Ventricular Dysfunction- Pre-clinical Phase Drug Mechanism of Action
7.4 Current Status
7.5 Trial Details
8 RECENT NEWS AND DEVELOPMENTS
9 APPENDIX
9.1 About VPAResearch
9.2 Sources and Research Methodology
